Baird analyst Jeff Johnson raised his price target on Henry Schein to $63 after hosting an investor lunch with management on Friday, telling investors that he came away believing the company remains well positioned to continue gaining share across both its dental and medical businesses and expanding its efforts in higher-margin software/services areas over time. The analyst maintains a Neutral rating, saying he doesn’t see a high likelihood of upside to this year’s EPS guidance, potentially keeping shares range bound in the upper $50s/low $60s over the next few quarters.
https://thefly.com/landingPageNews.php?id=2883667
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.